INDIANAPOLIS — Eli Lilly has paused it’s development of an antibody treatment for COVID-19. Lilly isn’t saying exactly why they are pausing clinical trials but that the decision was made “out of an abundance of caution.”
Pharmaceutical companies typically pause the development of treatments and vaccines when someone taking part in clinical trials gets sick, though Lilly is not saying if that is in fact the reason in this case.
AstraZeneca paused trials for their vaccine candidate because some got sick over a week ago, but those have since restarted. Johnson & Johnson just paused trials for their vaccine candidate on Monday.